ArticleGeburtshilfe und Frauenheilkunde2025

Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?

Stefan Lukac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.